九洲藥業(603456.SH)績後跳漲超6% Q3業績超預期
格隆匯10月29日丨昨晚公佈業績的九洲藥業(603456.SH)今日盤中一度漲超6%至53.46元,市值445億元。財報顯示,公司第三季度營收11.36 億元,同比增53.97%;歸母淨利潤1.98億元,再創單季新高,同比增80.39%;扣非淨利潤1.91億元,同比增111.40%。研究員稱,公司三季度業績超預期,已連續6個季度實現高增長。Q3利潤增速明顯高於收入端,預計是因公司收入結構升級,CDMO業務佔據收入比例增大所致。不過值得注意的一點是,公司合同負債科目環比出現明顯下降。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.